Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
Key takeaways
- (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
- The Fly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, securing exclusive rights to MIUDELLA, a hormone-free copper intrauterine device.
- The therapy is intended for multiple inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets? Laiba Immad Tue, June 30, 2026 at 8:08 PM GMT+7 2 min read OGN We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Organon & Co. (NYSE:OGN) is one of the best low-priced pharma stocks on this list.
The Fly reported on June 22 that OGN announced the completion of a global licensing agreement with Sebela Pharmaceuticals, securing exclusive rights to MIUDELLA, a hormone-free copper intrauterine device. Approved by the U.S. FDA in February 2025, MIUDELLA represents the first hormone-free copper IUD launched in the U.S. in more than four decades. The device is designed to prevent pregnancy for up to three years and offers 99% effectiveness. MIUDELLA incorporates SLIMSERT technology, featuring a flexible frame and preloaded insertion system with a 3.7mm tapered tube. The product is expected to become commercially available in late 2026.
Separately, on June 18, Organon & Co. (NYSE:OGN) and Samsung Bioepis announced an expansion of their development and commercialization partnership, with Organon gaining exclusive commercialization rights in Canada for Pyzchiva, a biosimilar referencing Stelara (ustekinumab). The therapy is intended for multiple inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Under the agreement, Samsung Bioepis will continue managing development, manufacturing, and regulatory responsibilities, while Organon will lead commercial activities in Canada. The expansion increases their Canadian biosimilar collaboration portfolio from five to six products, with Pyzchiva expected to launch in 2026.